Trial Profile
Open-label Study to Investigate the Pharmacokinetics and Safety of Tasimelteon in Children and Adolescents
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2019
Price :
$35
*
At a glance
- Drugs Tasimelteon (Primary)
- Indications Circadian rhythm sleep disorders
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Vanda Pharmaceuticals
- 02 Nov 2019 This trial has been discontinued in Germany as per European Clinical Trials Database record.
- 14 Feb 2018 Status changed from recruiting to active, no longer recruiting, according to a Vanda Pharmaceuticals media release.
- 07 Nov 2017 The study is expected to be fully enrolled by the end of 2017 according to a Vanda Pharmaceuticals media release.